CRISPR Therapeutics AG
NASDAQCRSP enters Tuesday's earnings report carrying one of the most crowded short positions in biotech — yet the bears have spent the past month quietly retreating. Short interest is running at 20.6% of the free float, a level that keeps CRSP firmly in the top tier of heavily shorted Nasdaq names. That number has real weight: it peaked even higher in early July, when roughly 24.9…
CRSP short interest climbs to 25.88% of float, up 20.8% in one week as gene-editing sentiment weakens.
Snapshot as of 6 Aug 2026
CRSP enters Tuesday's earnings report carrying one of the most crowded short positions in biotech — yet the bears have spent the past month quietly retreating. Short interest is running at 20.6% of the free float, a…
CRISPR Therapeutics heads into the second half of 2026 carrying one of the most charged short-side setups in biotech — short interest has jumped 20% in a single week while the stock trails its gene-editing peers by a…
CRISPR Therapeutics enters mid-May with one of the most heavily shorted profiles in the gene-editing space — yet the lending market has loosened meaningfully from its April extremes, creating a tension at the heart of…
CRSP heads into its May 11 earnings report carrying one of the most crowded short positions in biotech — and fresh evidence that options traders turned meaningfully more defensive this week. The options signal is the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CRSP — free to start on ORTEX.
Sign up for free →Open CRSP on ORTEX